EMA — authorised 15 May 2002
- Application: EMEA/H/C/000463
- Marketing authorisation holder: H. Lundbeck A/S
- Local brand name: Ebixa
- Indication: Treatment of patients with moderate to severe Alzheimer's disease.
- Status: approved
EMA authorised Memantine (once daily) on 15 May 2002
Yes. EMA authorised it on 15 May 2002.
H. Lundbeck A/S holds the EU marketing authorisation.